Find Research outputs

Search results

• Article

  Pharmacological inhibition of spermine oxidase reduces neurodegeneration and improves retinal function in diabetic mice

  Liu, F., Saul, A. B., Pichavaram, P., Xu, Z., Rudraraju, M., Somanath, P. R., Smith, S. B., Caldwell, R. B. & Narayanan, S. P., Feb 2020, In: Journal of Clinical Medicine. 9, 2, 340.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  15 Scopus citations

• Pharmacological interference with dimerization of human neuronal nitric-oxide synthase expressed in adenovirus-infected DLD-1 cells

  Habisch, H. J., Gorren, A. C. F., Liang, H., Venema, R. C., Parkinson, J. F., Schmidt, K. & Mayer, B., Mar 1 2003, In: Molecular pharmacology. 63, 3, p. 682-689 8 p.

  Research output: Contribution to journal › Article › peer-review
  15 Scopus citations

• Pharmacologically-induced neurovascular uncoupling is associated with cognitive impairment in mice

  Tarantini, S., Hertelendy, P., Tucsek, Z., Valcarcel-Ares, M. N., Smith, N., Menyhart, A., Farkas, E., Hodges, E. L., Towner, R., Deak, F., Sonntag, W. E., Csiszar, A., Ungvari, Z. & Toth, P., Nov 1 2015, In: Journal of Cerebral Blood Flow and Metabolism. 35, 11, p. 1871-1881 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  78 Scopus citations

• Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart

  Niagara, M. I., Haider, H. K., Jiang, S. & Ashraf, M., Mar 2007, In: Circulation research. 100, 4, p. 545-555 11 p.

  Research output: Contribution to journal › Article › peer-review
  156 Scopus citations

• Pharmacologically targeting the myristoylation of the scaffold protein FRS2 inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression

  Li, Q., Alsaidan, O. A., Ma, Y., Kim, S., Liu, J., Albers, T., Liu, K., Beharry, Z., Zhao, S., Wang, F., Lebedyeva, I. & Cai, H., Apr 27 2018, In: Journal of Biological Chemistry. 293, 17, p. 6434-6448 15 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  15 Scopus citations

• Pharmacological rescue in patient iPSC and mouse models with a rare DISC1 mutation

  Kim, N. S., Wen, Z., Liu, J., Zhou, Y., Guo, Z., Xu, C., Lin, Y. T., Yoon, K. J., Park, J., Cho, M., Kim, M., Wang, X., Yu, H., Salamuru, S., Christian, K. M., Hsu, K. S., Xia, M., Li, W., Ross, C. A., Margolis, R. L., & 3 othersLu, X. Y., Song, H. & Ming, G. L., Dec 2021, In: Nature communications. 12, 1, 1398.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  5 Scopus citations

• Pharmacological strategies in the prevention of relapse after electroconvulsive therapy

  Prudic, J., Haskett, R. F., McCall, W. V., Isenberg, K., Cooper, T., Rosenquist, P. B., Mulsant, B. H. & Sackeim, H. A., Mar 2013, In: Journal of ECT. 29, 1, p. 3-12 10 p.

  Research output: Contribution to journal › Article › peer-review
  66 Scopus citations

• Pharmacological studies of a new 4 aminosugar cardiac glycoside (ASI 222)

  Caldwell, R. W. & Nash, C. B., Dec 1 1976, In: Journal of Pharmacology and Experimental Therapeutics. 197, 1, p. 19-26 8 p.

  Research output: Contribution to journal › Article › peer-review
  19 Scopus citations

• Pharmacological studies of the therapy of shock

  Vick, J. A., Heiffer, M. H., Caldwell, R. W., Neis, A. & Roberts, C. R., Jan 1 1973, In: Medicine (United States). 52, 4, p. 279-285 7 p.

  Research output: Contribution to journal › Article › peer-review
  2 Scopus citations

• Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial

  Simons, M., Annex, B. H., Laham, R. J., Kleiman, N., Henry, T., Dauerman, H., Udelson, J. E., Gervino, E. V., Pike, M., Whitehouse, M. J., Moon, T. & Chronos, N. A., Feb 19 2002, In: Circulation. 105, 7, p. 788-793 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  573 Scopus citations

• Pharmacologic comparison of selected agonists for the M₁ muscarinic receptor in transfected murine fibroblast cells (B82)

  Mei, L., Lai, J., Yamamura, H. I. & Roeske, W. R., 1991, In: Journal of Pharmacology and Experimental Therapeutics. 256, 2, p. 689-694 6 p.

  Research output: Contribution to journal › Article › peer-review
  23 Scopus citations

• Pharmacologic comparison of the cloned M1 and M2 muscarinic receptors of the rat expressed in murine fibroblast cells

  Roeske, W. R., Lai, J., Mei, L., Bloom, J. W. & Yamamura, H. I., Jul 5 1990, In: European Journal of Pharmacology. 183, 5, 1 p.

  Research output: Contribution to journal › Article › peer-review

• Pharmacologic induction of fetal hemoglobin synthesis: Cellular and molecular mechanisms

  Yang, Y. M. & Pace, B. S., Dec 1 2001, In: Fetal and Pediatric Pathology. 20, 1, p. 87-106 20 p.

  Research output: Contribution to journal › Article › peer-review
  8 Scopus citations

• Pharmacologic management of asthma in childhood

  Wray, B. B., Nov 1978, In: Southern medical journal. 71, 11, p. 1387-1392+1396

  Research output: Contribution to journal › Article › peer-review

• Pharmacology and clinical experience with simvastatin

  Hess, D. C. & Fagan, S. C., May 22 2001, In: Expert Opinion on Pharmacotherapy. 2, 1, p. 153-163 11 p.

  Research output: Contribution to journal › Article › peer-review
  28 Scopus citations

• Pharmacology of the enantiomers of threo-methylphenidate

  Patrick, K. S., Caldwell, R. W., Ferris, R. M. & Breese, G. R., Jan 1 1987, In: Journal of Pharmacology and Experimental Therapeutics. 241, 1, p. 152-158 7 p.

  Research output: Contribution to journal › Article › peer-review
  190 Scopus citations

• Pharmacophore-based discovery of new human dihydroorotate dehydrogenase inhibitor

  Lu, P., Wang, Y., Ma, B., She, J., Zhang, Q., He, M. & Liu, Y., Jun 2014, In: Medicinal Chemistry. 10, 4, p. 402-408 7 p.

  Research output: Contribution to journal › Article › peer-review
  3 Scopus citations

• Pharmacotherapy of Impaired Affect in Recovering Schizophrenic Patients

  Hogarty, G. E., McEvoy, J. P., Ulrich, R. F., DiBarry, A. L., Bartone, P., Cooley, S., Hammill, K., Carter, M., Munetz, M. R. & Perel, J., Jan 1995, In: Archives of General Psychiatry. 52, 1, p. 29-41 13 p.

  Research output: Contribution to journal › Article › peer-review
  77 Scopus citations

• Pharmacy practice research: Understanding health-related quality of life

  MacKinnon, N. J. & Chaudhary, D. A. N., 1999, In: Canadian Pharmaceutical Journal. 132, 10, p. 33-34 2 p.

  Research output: Contribution to journal › Article › peer-review

• Pharyngeal Swallowing Mechanics Secondary to Hemispheric Stroke

  May, N. H., Pisegna, J. M., Marchina, S., Langmore, S. E., Kumar, S. & Pearson, W. G., May 2017, In: Journal of Stroke and Cerebrovascular Diseases. 26, 5, p. 952-961 10 p.

  Research output: Contribution to journal › Article › peer-review
  21 Scopus citations

• Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

  Halwani, A. S., Panizo, C., Isufi, I., Herrera, A. F., Okada, C. Y., Cull, E. H., Kis, B., Chaves, J. M., Bartlett, N. L., Ai, W., de la Cruz-Merino, L., Bryan, L. J., Houot, R., Linton, K., Briones, J., Chau, I., von Keudell, G. R., Lu, H., Yakovich, A., Chen, M., & 4 othersMeulen JH, T., Yurasov, S., Hsu, F. J. & Flowers, C. R., 2022, In: Leukemia and Lymphoma. 63, 4, p. 821-833 13 p.

  Research output: Contribution to journal › Article › peer-review
  1 Scopus citations

• Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia

  Garcia-Manero, G., Kantarjian, H. M., Sanchez-Gonzalez, B., Yang, H., Rosner, G., Verstovsek, S., Rytting, M., Wierda, W. G., Ravandi, F., Koller, C., Xiao, L., Faderl, S., Estrov, Z., Cortes, J., O'Brien, S., Estey, E., Bueso-Ramos, C., Fiorentino, J., Jabbour, E. & Issa, J. P., Nov 15 2006, In: Blood. 108, 10, p. 3271-3279 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  443 Scopus citations

• Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia

  Cortes, J., Podoltsev, N., Kantarjian, H., Borthakur, G., Zeidan, A. M., Stahl, M., Taube, T., Fagan, N., Rajeswari, S. & Uy, G. L., Jan 2021, In: International Journal of Hematology. 113, 1, p. 92-99 8 p.

  Research output: Contribution to journal › Article › peer-review
  7 Scopus citations

• Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

  Cortes, J., Talpaz, M., Smith, H. P., Snyder, D. S., Khoury, J., Bhalla, K. N., Pinilla-Ibarz, J., Larson, R., Mitchell, D., Wise, S. C., Rutkoski, T. J., Smith, B. D., Flynn, D. L., Kantarjian, H. M., Rosen, O. & Van Etten, R. A., Feb 28 2017, In: Haematologica. 102, 3, p. 519-528 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  16 Scopus citations

• Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies

  Yee, K. W. L., Hagey, A., Verstovsek, S., Cortes, J., Garcia-Manero, G., O'Brien, S. M., Faderl, S., Thomas, D., Wierda, W., Kornblau, S., Ferrajoli, A., Albitar, M., McKeegan, E., Grimm, D. R., Mueller, T., Holley-Shanks, R. R., Sahelijo, L., Gordon, G. B., Kantarjian, H. M. & Giles, F. J., Sep 15 2005, In: Clinical Cancer Research. 11, 18, p. 6615-6624 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  76 Scopus citations

• Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

  Borthakur, G., Rosenblum, M. G., Talpaz, M., Daver, N., Ravandi, F., Faderl, S., Freireich, E. J., Kadia, T., Garcia-Manero, G., Kantarjian, H. & Cortes, J. E., Feb 1 2013, In: Haematologica. 98, 2, p. 217-221 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  52 Scopus citations

• Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients

  Borthakur, G., Zeng, Z., Cortes, J. E., Chen, H. C., Huang, X., Konopleva, M., Ravandi, F., Kadia, T., Patel, K. P., Daver, N., Kelly, M. A., McQueen, T., Wang, R. Y., Kantarjian, H. & Andreeff, M., Nov 1 2020, In: American Journal of Hematology. 95, 11, p. 1296-1303 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  10 Scopus citations

• Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

  Lee, J. H., Faderl, S., Pagel, J. M., Jung, C. W., Yoon, S. S., Pardanani, A. D., Becker, P. S., Lee, H., Choi, J., Lee, K., Kim, M. & Cortes, J. E., May 12 2020, In: Blood Advances. 4, 9, p. 2032-2043 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  24 Scopus citations

• Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in philadelphia chromosome-positive leukemias after imatinib resistance or intolerance

  Kantarjian, H., Le Coutre, P., Cortes, J., Pinilla-Ibarz, J., Nagler, A., Hochhaus, A., Kimura, S. & Ottmann, O., Jun 1 2010, In: Cancer. 116, 11, p. 2665-2672 8 p.

  Research output: Contribution to journal › Article › peer-review
  47 Scopus citations

• Phase 1 study of Lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib

  Cortes, J., Jabbour, E., Daley, G. Q., O'Brien, S., Verstovsek, S., Ferrajoli, A., Koller, C., Zhu, Y., Statkevich, P. & Kantarjian, H., Sep 15 2007, In: Cancer. 110, 6, p. 1295-1302 8 p.

  Research output: Contribution to journal › Article › peer-review
  48 Scopus citations

• Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies

  Issa, J. P. J., Garcia-Manero, G., Giles, F. J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C. S., Cortes, J. & Kantarjian, H. M., Mar 1 2004, In: Blood. 103, 5, p. 1635-1640 6 p.

  Research output: Contribution to journal › Article › peer-review
  710 Scopus citations

• Phase 1 study of polyethylene glycol formulation of interferon α-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia

  Talpaz, M., O'Brien, S., Rose, E., Gupta, S., Shan, J., Cortes, J., Giles, F. J., Faderl, S. & Kantarjian, H. M., Sep 15 2001, In: Blood. 98, 6, p. 1708-1713 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  70 Scopus citations

• Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

  Roboz, G. J., Giles, F. J., List, A. F., Cortes, J. E., Carlin, R., Kowalski, M., Bilic, S., Masson, E., Rosamilia, M., Schuster, M. W., Laurent, D. & Feldman, E. J., Jun 2006, In: Leukemia. 20, 6, p. 952-957 6 p.

  Research output: Contribution to journal › Article › peer-review
  75 Scopus citations

• Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia

  Altman, J. K., Foran, J. M., Pratz, K. W., Trone, D., Cortes, J. E. & Tallman, M. S., Feb 2018, In: American Journal of Hematology. 93, 2, p. 213-221 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  55 Scopus citations

• Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

  Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W. G., Faderl, S., Koller, C., Morris, G., Rosner, G., Loboda, A., Fantin, V. R., Randolph, S. S., Hardwick, J. S., Reilly, J. F., Chen, C., Ricker, J. L., Secrist, J. P., Richon, V. M., Frankel, S. R., & 1 othersKantarjian, H. M., 2008, In: Blood. 111, 3, p. 1060-1066 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  395 Scopus citations

• Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

  Garcia-Manero, G., Assouline, S., Cortes, J., Estrov, Z., Kantarjian, H., Yang, H., Newsome, W. M., Miller, W. H., Rousseau, C., Kalita, A., Bonfils, C., Dubay, M., Patterson, T. A., Li, Z., Besterman, J. M., Reid, G., Laille, E., Martell, R. E. & Minden, M., Aug 15 2008, In: Blood. 112, 4, p. 981-989 9 p.

  Research output: Contribution to journal › Article › peer-review
  220 Scopus citations

• Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

  Cortes, J., Quintás-Cardama, A., Garcia-Manero, G., O'Brien, S., Jones, D., Faderl, S., Ebarb, T., Giles, F., Thomas, D. & Kantarjian, H., Nov 1 2007, In: Cancer. 110, 9, p. 2000-2006 7 p.

  Research output: Contribution to journal › Article › peer-review
  36 Scopus citations

• Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies

  Borthakur, G., Alvarado, Y., Ravandi-Kashani, F., Cortes, J., Estrov, Z., Faderl, S., Ivy, P., Bueso-Ramos, C., Bekele, B. N. & Giles, F., Jul 15 2008, In: Cancer. 113, 2, p. 360-366 7 p.

  Research output: Contribution to journal › Article › peer-review
  8 Scopus citations

• Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia

  Waldmann, T. A., Conlon, K. C., Stewart, D. M., Worthy, T. Y. A., Janik, J. E., Fleisher, T. A., Albert, P. S., Figg, W. D., Spencer, S. D., Raffeld, M., Decker, J. R., Goldman, C. K., Bryant, B. R., Petrus, M. N., Creekmore, S. P. & Morris, J. C., Jul 17 2013, In: Blood. 121, 3, p. 476-484 9 p.

  Research output: Contribution to journal › Article › peer-review
  48 Scopus citations

• Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

  Krause, D. S., Reinhardt, J., Vazquez, J. A., Reboli, A., Goldstein, B. P., Wible, M. & Henkel, T., Jun 2004, In: Antimicrobial agents and chemotherapy. 48, 6, p. 2021-2024 4 p.

  Research output: Contribution to journal › Article › peer-review
  153 Scopus citations

• Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML

  Cortes, J. E., Tallman, M. S., Schiller, G. J., Trone, D., Gammon, G., Goldberg, S. L., Perl, A. E., Marie, J. P., Martinelli, G., Kantarjian, H. M. & Levis, M. J., Aug 9 2018, In: Blood. 132, 6, p. 598-607 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  91 Scopus citations

• Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

  Kantarjian, H., Gandhi, V., Cortes, J., Verstovsek, S., Du, M., Garcia-Manero, G., Giles, F., Faderl, S., O'Brien, S., Jeha, S., Davis, J., Shaked, Z., Craig, A., Keating, M., Plunkett, W. & Freireich, E. J., Oct 1 2003, In: Blood. 102, 7, p. 2379-2386 8 p.

  Research output: Contribution to journal › Article › peer-review
  269 Scopus citations

• Phase 2 clinical trial of rapamycin-resistant donor CD4⁺ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation

  Fowler, D. H., Mossoba, M. E., Steinberg, S. M., Halverson, D. C., Stroncek, D., Khuu, H. M., Hakim, F. T., Castiello, L., Sabatino, M., Leitman, S. F., Mariotti, J., Gea-Banacloche, J. C., Sportes, C., Hardy, N. M., Hickstein, D. D., Pavletic, S. Z., Rowley, S., Goy, A., Donato, M., Korngold, R., & 5 othersPecora, A., Levine, B. L., June, C. H., Gress, R. E. & Bishop, M. R., Apr 11 2013, In: Blood. 121, 15, p. 2864-2874 11 p.

  Research output: Contribution to journal › Article › peer-review
  25 Scopus citations

• Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

  Cortes, J., Kantarjian, H., Ball, E. D., DiPersio, J., Kolitz, J. E., Fernandez, H. F., Goodman, M., Borthakur, G., Baer, M. R. & Wetzler, M., Jan 15 2012, In: Cancer. 118, 2, p. 418-427 10 p.

  Research output: Contribution to journal › Article › peer-review
  23 Scopus citations

• Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

  Ravandi, F., Alattar, M. L., Grunwald, M. R., Rudek, M. A., Rajkhowa, T., Richie, M. A., Pierce, S., Daver, N., Garcia-Manero, G., Faderl, S., Nazha, A., Konopleva, M., Borthakur, G., Burger, J., Kadia, T., Dellasala, S., Andreeff, M., Cortes, J., Kantarjian, H. & Levis, M., Jun 6 2013, In: Blood. 121, 23, p. 4655-4662 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  295 Scopus citations

• Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

  Santos, F. P. S., Kantarjian, H. M., Jain, N., Manshouri, T., Thomas, D. A., Garcia-Manero, G., Kennedy, D., Estrov, Z., Cortes, J. & Verstovsek, S., Feb 11 2010, In: Blood. 115, 6, p. 1131-1136 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  183 Scopus citations

• Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia

  Sasaki, K., Kantarjian, H., Wierda, W., Ravandi-Kashani, F., Jorgensen, J., Wang, S. A., Khoury, J., Daver, N., Burger, J., Di Nardo, C. D., Jain, N., Short, N. J., Estrov MD, Z., Konopleva MD, PhD, M., Ohanian DO, M., Garcia-Manero, G., Kadia, T., Alvarado-Valero, Y., Yilmaz, M., Pierce, S., & 5 othersGarris, R., Ingram, A., Cortes, J., OʼBrien, S. & Jabbour, E., Jul 1 2020, In: American Journal of Hematology. 95, 7, p. 734-739 6 p.

  Research output: Contribution to journal › Article › peer-review
  6 Scopus citations

• Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission

  Abou Dalle, I., Kantarjian, H. M., Ravandi, F., Daver, N., Wang, X., Jabbour, E., Estrov, Z., DiNardo, C. D., Pemmaraju, N., Ferrajoli, A., Jain, N., Wang, S. A., Jammal, N., Borthakur, G., Naqvi, K., Pelletier, S., Pierce, S., Andreeff, M., Garcia-Manero, G., Cortes, J. E., & 1 othersKadia, T. M., Jun 1 2021, In: Cancer. 127, 11, p. 1894-1900 7 p.

  Research output: Contribution to journal › Article › peer-review
  1 Scopus citations

• Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

  Cortes, J., Lipton, J. H., Rea, D., Digumarti, R., Chuah, C., Nanda, N., Benichou, A. C., Craig, A. R., Michallet, M., Nicolini, F. E. & Kantarjian, H., Sep 27 2012, In: Blood. 120, 13, p. 2573-2580 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  113 Scopus citations

• Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

  Cortes, J., Digumarti, R., Parikh, P. M., Wetzler, M., Lipton, J. H., Hochhaus, A., Craig, A. R., Benichou, A. C., Nicolini, F. E. & Kantarjian, H. M., May 2013, In: American Journal of Hematology. 88, 5, p. 350-354 5 p.

  Research output: Contribution to journal › Article › peer-review
  51 Scopus citations